Look no further than our top two stories of the year, and you’ll see that the GLP-1 craze and Big Pharma layoffs took center ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in metabolic dysfunction-associated steatohepatitis, WHIM syndrome and pediatric ...

2. Madrigal’s Rezdiffra (resmetirom) for NASH/MASH Madrigal is turning biotech heads with its launch of NASH drug Rezdiffra, which notched an FDA approval March 14 as the first treatment for the liver ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

As the first oral treatment for NASH without direct competition, Rezdiffra has positioned Madrigal as a potential leader in addressing this growing health concern. Rezdiffra, Madrigal's primary ...

As the first oral treatment for NASH without direct competition, Rezdiffra has positioned Madrigal as a potential leader in addressing this growing health concern. Rezdiffra, Madrigal's primary ...

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and ...